Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) a specialty pharmaceutical company is surging in the market after providing data on the efficacy of ADS-5102, a treatment for levodopa-induced dyskinesia. This is a serious health condition associated with the treatment of Parkinson’s. The presented data included assessment of patients receiving the treatment using Clinical Global Impression of Change metric. Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) shares after opening at $18.69 moved to $21.63 on last trade day and at the end of the day closed at $20.07. Company price to sales ratio in past twelve months was calculated as 4.64 and price to cash ratio as 3.85. Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) showed a positive weekly performance of 25.59%.
Bayer AG (BAYN) is in exclusive talks to acquire Merck & Co. (NYSE:MRK) consumer business and is prepared to pay about $14 billion for the division, people with knowledge of the matter said. Merck & Co., Inc. (NYSE:MRK) shares advanced 1.81% in last trading session and ended the day on $59.62. MRK return on equity ratio is recorded as 12.10% and its return on assets is 5.60%. Merck & Co., Inc. (NYSE:MRK) yearly performance is 35.13%.
Allergan Inc. (NYSE:AGN) has contacted companies including Sanofi (SAN) and Johnson & Johnson (JNJ) to see if either would be interested in acquiring the Botox maker, said people with knowledge of the matter, as it explores its options after receiving an unsolicited $45.7 billion bid from Valeant Pharmaceuticals International Inc. Allergan, Inc. (NYSE:AGN) shares moved up 1.72% in last trading session and was closed at $168.69, while trading in range of $165.96 – $170.05. Allergan, Inc. (NYSE:AGN) year to date (YTD) performance is 51.92%.
Novartis AG (ADR) (NYSE:NVS) net income growth from the same quarter one year ago has exceeded that of the Pharmaceuticals industry average, but is less than that of the S&P 500. The net income increased by 22.6% when compared to the same quarter one year prior, going from $2,398.00 million to $2,941.00 million. Novartis AG (ADR) (NYSE:NVS) weekly performance is 2.85%. On last trading day company shares ended up $87.00. Novartis AG (ADR) (NYSE:NVS) distance from 50-day simple moving average (SMA50) is 4.87%. Analysts mean target price for the company is $85.01.